| Patient | Voltaire |
|---|---|
| Date of birth | 1942-11-21 |
| Identifiers | MRN HR-EN002-SYN; SSN (made up) 000-02-5174 |
| Document date | 2026-04-22 |
| Author | Honorine Delacroix-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review of the resection pathology and a trial without catheter; decision on treatment. [S]
Voltaire returns a week after the transurethral resection and two days after the sick visit for a catheter-associated infection. He has been afebrile since yesterday morning on cefpodoxime, and the culture grew Escherichia coli sensitive to it. The urine is pale pink without clots. Since the resection he has had a burning ache above the pubic bone and bladder spasms, worst in the evening, rated 5 of 10; acetaminophen when he remembers takes the edge off. He asked for something strong, saying that a friend has offered him drops made with opium. He has had no constipation on polyethylene glycol. The trial without catheter began this morning: the catheter was removed at 8 am and he voided 260 mL before this visit. He came with his assistant and wants to hear the results plainly and to decide today. [S]
| Element | Detail |
|---|---|
| Pathology | Keratinizing squamous cell carcinoma invading the muscularis propria, with lymphovascular invasion; no urothelial component or carcinoma in situ |
| Infection | Afebrile on day 3 of cefpodoxime; Escherichia coli sensitive |
| Pain | Suprapubic burning and evening spasm, 5 of 10 |
| Voiding trial | Catheter out this morning; voided 260 mL; residual 140 mL |
| IPSS | 14 (moderate), from 22 before the catheter |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired after the infection; no fever since yesterday morning; appetite small |
| Genitourinary | Positive | Pale pink urine, frequency, burning, and evening spasm after resection; no clots |
| Gastrointestinal | Negative | Bowels open daily |
| Musculoskeletal | Negative | No bone pain |
| Psychiatric | Positive | Shaken by the diagnosis but composed; wants to keep working |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Diphenhydramine 25 mg oral capsule, one capsule at night for sleep (over the counter) | One capsule at bedtime | Oral route | 2025-09-01 to 2026-04-06 | stopped | S |
| Tamsulosin 0.4 mg oral capsule, one capsule at bedtime | One capsule 30 minutes after the evening meal | Oral route | 2026-04-06 | active | S |
| Polyethylene glycol 3350, 17 g in a glass of water once daily | 17 g dissolved in water once daily | Oral route | 2024-01-15 | active | S |
| Cefpodoxime 200 mg oral tablet, one tablet by mouth twice daily for 7 days | One tablet twice daily with food for 7 days | Oral route | 2026-04-20 to 2026-04-26 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth three times daily (3 g a day) | Two tablets three times daily; no more than 3 g a day | Oral route | 2026-04-22 | active | S |
| Oxycodone 5 mg oral tablet, one half tablet (2.5 mg) by mouth every 6 hours if needed for bladder pain not relieved by acetaminophen, no more than three doses a day; 15 tablets dispensed | Half a tablet every 6 hours as needed; no more than three half tablets a day | Oral route | 2026-04-22 | active | S |
| Sennosides 8.6 mg oral tablet, two tablets at bedtime while taking oxycodone | Two tablets at bedtime | Oral route | 2026-04-22 | active | S |
| Naloxone 4 mg nasal spray, one spray in one nostril for suspected opioid overdose; call 911; may repeat in 2 to 3 minutes in the other nostril | One spray for suspected overdose; repeat after 2 to 3 minutes if no response | Nasal route | 2026-04-22 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-22 | Body height | 170 | cm | S |
| 2026-04-22 | Body weight | 53.4 | kg | S |
| 2026-04-22 | Body mass index (BMI) [Ratio] | 18.5 | kg/m2 | S |
| 2026-04-22 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-04-22 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-04-22 | Heart rate | 82 | /min | S |
| 2026-04-22 | Respiratory rate | 16 | /min | S |
| 2026-04-22 | Body temperature | 36.9 | Cel | S |
| 2026-04-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-22 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-04-22 | Leukocytes [#/volume] in Blood by Automated count | 8.2 | 10*3/uL | 3.4-9.6 10*3/uL | Normal | S |
| 2026-04-22 | Platelets [#/volume] in Blood by Automated count | 254 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-22 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-22 | Creatinine [Mass/volume] in Serum or Plasma | 1.22 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-04-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 59 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-04-22 | US Urinary bladder Volume post void | 140 | mL | Below 100 mL; 300 mL or more suggests chronic retention | High | S |
| 2026-04-22 | International Prostate Symptom Score [IPSS] | 14 | {score} | S | ||
| 2026-04-22 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | {score} | S |
Vital signs recorded on 2026-04-22; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, alert, and engaged; temperature 36.9 C |
| Cardiovascular | Blood pressure 124/68 mmHg; heart rate 82, regular |
| Abdomen | Mild suprapubic tenderness; bladder not palpable after voiding; no masses |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Visible blood in the urine for three weeks with clots, and a weak stream, straining, and frequent small voids, in a man of 83; under evaluation | resolved | confirmed | R31.0 | S — Synthetic presenting problem echoing his documented urinary complaints and last illness; superseded by the diagnosis at the third chronic-care visit. |
| Chronic urinary retention with overflow (post-void residual 460 mL at intake), worsened by a nightly anticholinergic sleep aid; drained by an indwelling catheter | active | confirmed | R33.8 | S — Synthetic finding echoing the strangury and catheterization documented in his last weeks. |
| Acute kidney injury from bladder outlet obstruction (creatinine 1.68 mg/dL, from 1.1 mg/dL a year earlier) | resolved | confirmed | N17.9 | S — Synthetic finding; it echoes, without asserting, the later encyclopedia term uremia. |
| Benign prostatic hyperplasia with lower urinary tract symptoms: prostate about 78 mL on CT, enlarged, firm, and smooth on examination, PSA 6.4 ng/mL with a PSA density of 0.08; no prostate biopsy, by shared decision | active | confirmed | N40.1 | S — Synthetic diagnosis echoing the very large prostate described at the 1778 autopsy; whether that prostate was malignant is unknown (CLM-0012). |
| Squamous cell carcinoma of the bladder, keratinizing, posterior wall extending to the dome, muscle-invasive with extravesical extension (clinical stage cT3b N0 M0, stage IIIA), pure squamous histology without a urothelial component; treated with palliative-intent hypofractionated radiotherapy by shared decision | active | confirmed | C67.4 | S — Synthetic modern diagnosis confirmed by resection pathology. His bladder disease at autopsy is documented (D); calling it squamous cell carcinoma is a 2025 retrospective interpretation (R, disputed). |
| Chronic constipation, lifelong by his account, with long use of laxatives and self-given enemas | active | confirmed | K59.09 | S — Synthetic modern problem echoing his documented colic, purges, and enemas; no diagnosis of inflammatory bowel disease is made. |
| Febrile catheter-associated urinary tract infection with Escherichia coli, five days after bladder tumor resection; treated with cefpodoxime and a catheter change; resolved | active | confirmed | T83.511A | S — Synthetic intercurrent infection; it echoes, without asserting, the infected urine described in his last weeks (CLM-0009). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count and kidney function before radiotherapy and before an opioid | Before treatment, then at each visit during treatment | Completed today | Hemoglobin 10.9 g/dL, white count 8.2, platelets 254; creatinine 1.22 mg/dL (eGFR 59), potassium 4.5 mmol/L |
| Laboratory | Urine culture from the sick visit | With symptoms of catheter-associated infection | Completed today | Escherichia coli sensitive to cefpodoxime; no change of antibiotic |
| Imaging | Staging: chest imaging and CT or MRI of the abdomen and pelvis | Before treatment of muscle-invasive bladder cancer | Completed today | CT urography and chest CT reviewed with the pathology: cT3b N0 M0; bone scan not needed without bone pain |
| Examination | Post-void residual after the trial without catheter | At baseline when retention is suspected, after a trial without catheter, and when symptoms change | Completed today | 140 mL after voiding 260 mL |
| Survey | IPSS | Baseline and at every follow-up visit (CMID BPH) | Completed today | 14, moderate, from 22 before the catheter |
| Survey | Pain intensity (0 to 10) | At every visit with cancer pain, and before and after any opioid | Completed today | 5 of 10, suprapubic |
| Examination | Geriatric assessment before cancer treatment (G8 screen, function, nutrition, comorbidity, social support) | Before choosing cancer treatment in adults 65 and older | Completed today | G8 11 of 17; independent in self-care, needs help with shopping and travel; BMI 18.5; lives with an assistant. Cognitive screen and Timed Up and Go are booked for the wellness visit next week |
| Medication safety | Opioid start: risk review, prescription monitoring program, naloxone, bowel regimen, lowest dose of an immediate-release opioid, and a follow-up date | At the start, then within 1 to 4 weeks | Completed today | Prescription monitoring program clear; no benzodiazepine or other sedative; naloxone and senna prescribed; oxycodone 2.5 mg as needed, 15 tablets; review in two weeks |
| Medication safety | Alpha-blocker tolerability | At each visit in a frail older adult | Completed today | No dizziness; blood pressure 124/68 mmHg |
| Referral | Radiation oncology and palliative care | When treatment is chosen | Referred | Planning scan and the first fraction next week; palliative care home visit within two weeks |
| Imaging | Bladder cancer surveillance schedule (cystoscopy and cytology for NMIBC; CT every 6 to 12 months after cystectomy) | Applies after NMIBC treatment or cystectomy | Not indicated | Neither applies: he has muscle-invasive disease treated with palliative-intent radiotherapy, so response is judged by symptoms, with cystoscopy or CT only if they would change care |
Goal progress:
Guideline basis: Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024) (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026); EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer (2026); Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment (Hafeez S, et al.) (2017); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023); Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America (2009); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023); Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology (2018); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026)
Follow-up: Wellness visit next week; chronic-care review in two weeks, on the day of the second radiotherapy fraction; call for a falling stream, clots, fever, or pain not controlled. Next scheduled visit 2026-04-28: subsequent annual wellness visit at 83. [S]